Tanguler Tolga 4

What Happened Tanguler Tolga, a director of Lexeo Therapeutics, was granted/acquired derivative securities covering 35,000 shares on 2026-06-25. The Form 4 reports the acquisition at $0.00 (derivative award/option style grant). This is a grant/award (code A), not a sale — typically considered a compensation/retention award rather than an open‑market purchase.

Key Details

• Transaction date: 2026-06-25; Form 4 filed: 2026-06-29.
• Transaction type: Grant/Award of derivative securities (Form 4 code A).
• Amount: 35,000 shares reported as acquired at $0.00.
• Vesting: Footnote states 100% of the shares underlying the option vest and become exercisable on the earlier of one year after grant or the next annual meeting, subject to continuous service.
• Post-transaction holdings: Not specified in the details provided here — see the full Form 4 for the insider’s total beneficial ownership.
• Timeliness: The filing date is listed as 2026-06-29 for a 2026-06-25 transaction; Form 4s are generally required within two business days, so review the filing for any late-filing disclosure.

Context This was a derivative award (likely stock options or restricted stock units) issued as compensation/retention to a director. Such awards are common for board members and don’t necessarily indicate immediate buying/selling sentiment. The vesting schedule means the shares/options are not immediately exercisable or transferable until the vesting condition is met. For full details and to confirm exact instrument type and any tax-withholding provisions, consult the complete Form 4 filing (Accession 0001849458-26-000001).